Search clinical trials for: Surufatinib

Total 85 results

Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

Intrahepatic Cholangiocarcinoma

China
Hutchmed

Not yet recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Rui-hua Xu, MD, PhD

Not yet recruiting

A Phase II Study of Surufatinib Combined With PD-L1 and mFOLFOX6 as Second-line Treatment for Advanced PRAD

Advanced Pancreatic Cancer

China
Fudan University

Not yet recruiting

Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
China Medical University, China

Not yet recruiting

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
Qilu Hospital of Shandong University
BeiGene

Recruiting

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Changhai Hospital

Not yet recruiting

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor

China
Shanghai Changzheng Hospital

Not yet recruiting

A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Advanced Solid Tumors With Neuroendocrine Differentiation
Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological
Fudan University

Not yet recruiting

A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma Adult
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
Fudan University

Recruiting

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaborators

Not yet recruiting

Surufatinib in G3 Neuroendocrine Tumors

Neuroendocrine Tumor Grade 3
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

Osteosarcoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Fujian Cancer Hospital
Hunan Cancer Hospital; Wuhan TongJi Hospital

Not yet recruiting

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Fudan University

Recruiting

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma (IRIS)

High-Risk Localized Soft Tissue Sarcoma

China
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

Neuroendocrine Carcinoma

China
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients

Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients
Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Bai-Rong Xia

Recruiting

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Pancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy Effect | Angiogenesis
Brigham and Women's Hospital
University of California, Los Angeles; University of Stellenbosch; University... and other collaborators

Recruiting

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PRESCIENT)

HIV | Tuberculosis, Pulmonary

South Africa, Haiti
Wuhan Union Hospital, China

Not yet recruiting

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Unresectable Advanced Solid Tumors | Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Sun Yat-sen University
Hutchmed

Recruiting

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma | Fallopian Tube Carcinosarcoma

China
Sun Yat-sen University

Recruiting

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Neoplasms

China
Sun Yat-sen University

Recruiting

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
Sun Yat-sen University

Recruiting

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Metastatic | Adenocarcinoma of Small Intestine | Appendix Carcinoma

China
Hubei Cancer Hospital

Recruiting

Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

Colorectal Neoplasms

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Sun Yat-sen University

Recruiting

A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer

Gastric Adenocarcinoma

China
Tongji Hospital

Recruiting

A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC (CCGLC-005)

Intrahepatic Cholangiocarcinoma

China
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Breast Cancer | Breast Cancer Female

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples

Hepatocellular Carcinoma

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Sun Yat-sen University

Recruiting

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma

Sarcoma

China
Qilu Hospital of Shandong University

Not yet recruiting

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Biliary Tract Carcinoma
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer

Biliary Tract Cancer

China
Peking University

Recruiting

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Refractory Metastatic Digestive System Carcinoma

China

3

Subscribe